List of Excipients in Branded Drug XERAVA

« Back to Dashboard

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Tetraphase Pharmaceuticals Inc	XERAVA	eravacycline	71773-050	HYDROCHLORIC ACID	2032-08-27
Tetraphase Pharmaceuticals Inc	XERAVA	eravacycline	71773-050	MANNITOL	2032-08-27
Tetraphase Pharmaceuticals Inc	XERAVA	eravacycline	71773-050	SODIUM HYDROXIDE	2032-08-27

XERAVA Excipient Strategy and Commercial Opportunities

Last updated: August 25, 2026

XERAVA (eravacycline) is an intravenously administered tetracycline antibiotic for complicated intra-abdominal infections in adults. Its commercial excipient opportunity is concentrated in parenteral presentation, reconstitution, infusion compatibility, stability, and hospital-use logistics rather than in a broad oral solid-dose platform.

The current product is a single-dose, 50 mg lyophilized vial. The formulation uses mannitol as a bulking agent and hydrochloric acid for pH adjustment. XERAVA is reconstituted and diluted before intravenous infusion, creating commercial opportunities for ready-to-use bags, premixed presentations, improved in-use stability, and hospital compounding reduction.[1]

What excipients are used in XERAVA?

XERAVA contains eravacycline dihydrochloride in a lyophilized injectable formulation.

Formulation element	XERAVA role	Commercial relevance
Eravacycline dihydrochloride	Active pharmaceutical ingredient	Broad-spectrum tetracycline antibiotic
Mannitol	Bulking and lyophilization excipient	Supports cake structure and vial recovery
Hydrochloric acid	pH adjustment	Controls formulation pH and drug stability
Sterile Water for Injection	Reconstitution diluent	Used before further dilution
5% Dextrose Injection	Final dilution medium	Label-specified infusion vehicle

The FDA prescribing information identifies mannitol and hydrochloric acid as inactive ingredients. The commercial formulation is supplied as a sterile yellow-to-orange lyophilized powder in a single-dose vial.[1]

The product is not marketed as an oral tablet, capsule, inhaled product, depot injection, or prefilled syringe. That limits the immediate excipient market to sterile injectable and infusion-related technologies.

How does the XERAVA formulation work in hospital use?

XERAVA requires a multistep preparation process. The vial is reconstituted, inspected, diluted in 5% dextrose injection, and administered by intravenous infusion over approximately 60 minutes.[1]

The label directs preparation at a final concentration of 0.25 mg/mL. A 50 mg vial therefore produces a standard 200 mL final infusion volume at the labeled concentration. The preparation workflow creates several points where excipient and delivery-system companies can compete:

1. Improve reconstitution time and powder dissolution.
2. Extend post-reconstitution and post-dilution stability.
3. Reduce adsorption to bags, tubing, and connectors.
4. Support smaller-volume infusion for fluid-restricted patients.
5. Provide ready-to-administer presentations that avoid bedside compounding.
6. Improve protection from light, oxygen, and temperature excursions.

The most commercially relevant product would not necessarily replace the approved vial. A compatible premixed infusion bag or pharmacy bulk presentation could capture hospital labor savings while preserving the approved active ingredient and dose.

What excipient opportunities exist for XERAVA?

Mannitol optimization

Mannitol is the principal lyophilization-support excipient identified in the approved formulation. Its value is functional rather than therapeutic. It contributes to cake formation, vial appearance, fill-volume consistency, and reconstitution performance.

Potential development opportunities include:

• Particle-size control for improved dissolution.
• Low-endotoxin and low-bioburden grades for sterile manufacturing.
• Improved cake integrity during transport.
• Reduced vial-wall adhesion.
• Compatibility with alternative vial and stopper systems.
• Optimized mannitol-to-drug ratios for higher-concentration formulations.

A supplier seeking XERAVA-related business should focus on injectable-grade mannitol with validated extractables, elemental impurities, endotoxin, and particulate profiles. A simple substitution claim would have limited commercial value unless it produced measurable improvements in reconstitution, stability, or manufacturing yield.

pH-control systems

Hydrochloric acid is used for pH adjustment. A reformulation strategy could evaluate buffer systems, but this area carries a high technical burden. Buffers can alter eravacycline degradation, color, solubility, complexation, and compatibility with infusion materials.

Potential candidates include low-capacity citrate, acetate, phosphate, or histidine systems. Each would require direct comparative testing because tetracycline-class compounds can interact with divalent and trivalent cations and can be sensitive to pH and light exposure.

The strongest opportunity is a low-buffer or buffer-free formulation that maintains the current stability profile while reducing pH drift. A new buffer system would likely require a meaningful chemistry, manufacturing, and controls change and could trigger supplemental FDA review.

Solubilizers and stabilizers

XERAVA is supplied as a lyophilized powder, which indicates that the development team prioritized solid-state stability over a liquid concentrate. Solubilizers and stabilizers could support a liquid formulation, but the commercial case depends on preserving drug potency and controlling degradation products.

Relevant classes include:

• Polyols other than mannitol.
• Amino-acid stabilizers.
• Cyclodextrin derivatives.
• Surfactants at low concentrations.
• Antioxidant systems.
• Chelation-control strategies.

Surfactants and cyclodextrins can create new risks involving hemolysis, infusion tolerance, container interaction, and regulatory qualification. They should be evaluated only when they enable a clear benefit such as a stable liquid product, higher concentration, reduced infusion volume, or longer in-use storage.

What formulations are protected by XERAVA-related patents?

XERAVA’s principal intellectual-property position is expected to center on eravacycline composition, synthetic processes, therapeutic use, and formulation-related claims. Excipients may support a separate formulation patent only when the combination produces a defined technical result.

A commercially meaningful formulation patent would typically require claims directed to:

• Eravacycline with a specified excipient ratio.
• A defined pH range.
• A lyophilized cake with specified residual moisture.
• A reconstituted solution with defined stability.
• A particular infusion concentration.
• Reduced impurity formation.
• Compatibility with a specified container or administration system.
• A ready-to-use liquid or premixed bag.

Mannitol alone is unlikely to create a strong blocking position because it is a conventional injectable excipient. Patent value would be higher where the formulation demonstrates an unexpected stability, concentration, or administration advantage.

Orange Book status and small-molecule exclusivity

XERAVA is a small-molecule product. Biosimilar litigation does not apply. A future competitor would generally use the abbreviated new drug application pathway and could challenge listed patents through a Paragraph IV certification.

The FDA approved XERAVA on August 27, 2018, for complicated intra-abdominal infections in adults.[2] The product received Qualified Infectious Disease Product status, which can extend applicable regulatory exclusivity by five years. New chemical entity exclusivity and QIDP-related exclusivity are distinct from patent protection and do not prevent all forms of patent challenge after their statutory periods expire.[3]

Protection category	XERAVA relevance
New chemical entity exclusivity	Applied from the 2018 approval date, subject to statutory exceptions
QIDP exclusivity	Provides a five-year extension to qualifying exclusivity and patent terms
Orange Book patents	Potentially block approved generic launch if valid and enforceable
Formulation patents	May protect specific liquid, lyophilized, stability, or delivery systems
Method-of-use patents	May cover selected infection indications or dosing regimens
Biosimilar pathway	Not applicable to eravacycline

The FDA Orange Book remains the controlling source for currently listed patents, expiration dates, pediatric extensions, and exclusivity codes.[4] Excipient suppliers should not assume that a new excipient composition is free of patent risk merely because the excipient itself is old. A formulation patent can claim the active ingredient-excipient combination or a defined manufacturing process.

When does XERAVA lose exclusivity?

The regulatory exclusivity period began with the 2018 approval. QIDP status can extend qualifying exclusivity and patent protection by five years, placing the key regulatory horizon approximately five years beyond the ordinary five-year NCE period.

Patent expiry may extend beyond regulatory exclusivity. The commercial entry date for a generic would depend on:

• The expiration of listed patents.
• Any pediatric patent-term extension.
• Paragraph IV litigation.
• A settlement agreement.
• FDA approval timing.
• First-filer exclusivity.
• Manufacturing readiness.

A generic could receive approval before commercial launch if it obtains a favorable court ruling, settles with the patent holder, or accepts a delayed-entry date. A formulation-specific competitor could also develop a different excipient system while avoiding claims directed to the original lyophilized composition.

Which companies could challenge XERAVA?

Potential challengers are more likely to be injectable generic manufacturers with sterile lyophilization capacity than conventional oral-solid-dose companies.

The relevant competitor groups include:

• Large generic manufacturers with injectable portfolios.
• Contract development and manufacturing organizations.
• Specialty antibiotic companies.
• Hospital-injectable suppliers.
• Developers of ready-to-administer antibiotic bags.
• Companies pursuing differentiated 505(b)(2) products.

An ANDA challenger would need to demonstrate pharmaceutical equivalence, bioequivalence where applicable, sterility, container-closure integrity, and manufacturing control. A 505(b)(2) applicant could pursue a materially different formulation, concentration, delivery system, or administration method while relying partly on the XERAVA reference product.

What commercial opportunities exist in XERAVA excipient supply?

Ready-to-use infusion systems

The highest-value opportunity is a ready-to-use presentation that reduces pharmacy preparation. A premixed bag could eliminate vial reconstitution and dilution, reduce preparation errors, and improve adoption in hospitals with high antibiotic volume.

The technical requirements include:

• Long-term stability in the selected bag material.
• Compatibility with tubing and connectors.
• Low particulate formation.
• Controlled degradation products.
• Validated sterility throughout shelf life.
• Acceptable light protection.
• Consistent 0.25 mg/mL concentration.

Reduced-volume formulations

The labeled 200 mL final volume may be inconvenient for patients requiring fluid restriction. A higher-concentration formulation could reduce infusion volume if it preserves tolerability and stability.

This opportunity has clinical and regulatory value but also carries risk. Higher concentrations can increase precipitation, adsorption, local irritation, and infusion-line compatibility problems. A formulation that permits a 50 to 100 mL final volume could support hospital differentiation if supported by clinical and compatibility data.

Extended-stability products

The product label imposes handling and storage requirements after reconstitution and dilution.[1] A formulation with longer refrigerated or room-temperature stability could reduce pharmacy waste and support decentralized care.

Commercial value would be strongest in:

• Outpatient parenteral antimicrobial therapy.
• Hospital emergency departments.
• Long-term acute-care facilities.
• Smaller hospitals without 24-hour pharmacy compounding.
• Home-infusion providers.

Container-closure and administration components

Commercial opportunity extends beyond the excipient itself. Drug-device combinations could include:

• Low-sorption infusion bags.
• Light-protective overwraps.
• Compatible closed-system transfer devices.
• Preassembled infusion sets.
• Dual-chamber bags separating drug and diluent until use.
• Smaller-volume containers.

These products could be protected through device, process, or combination patents even where the excipient composition remains conventional.

What manufacturing barriers affect XERAVA formulation competition?

Sterile lyophilization is the primary manufacturing barrier. A competitor must control:

• Aseptic filling.
• Lyophilizer cycle development.
• Residual moisture.
• Cake appearance and collapse temperature.
• Reconstitution time.
• Sterility assurance.
• Container-closure integrity.
• Particulate contamination.
• Eravacycline degradation products.
• Light exposure during manufacture and storage.

Tetracycline-class chemistry also creates compatibility concerns with calcium, magnesium, aluminum, and iron. Diluent selection, equipment contact surfaces, and administration materials should be screened for metal-ion contamination and adsorption.

A differentiated excipient supplier can gain commercial leverage by providing a complete package: injectable-grade excipient, formulation development, lyophilization-cycle support, stability data, regulatory documentation, and supply continuity.

How strong is the excipient patent opportunity for XERAVA?

The patent opportunity is moderate for conventional excipients and stronger for integrated formulation systems.

Opportunity	Likely patent strength	Commercial assessment
Mannitol substitution alone	Low	Easy to design around
New mannitol grade or particle specification	Low to moderate	Valuable if it improves manufacturing
Novel buffer system	Moderate	Requires strong stability evidence
Stable liquid eravacycline formulation	Moderate to strong	Could support a differentiated product
High-concentration infusion	Moderate to strong	Potentially valuable for fluid-restricted patients
Ready-to-use bag	Moderate	Combination of formulation and device claims
Dual-chamber presentation	Stronger	Can create device and process barriers
Improved light-protection package	Low to moderate	Commercially useful, harder to block broadly
New administration device	Moderate to strong	May support 505(b)(2) or combination-product strategy

What litigation and settlement risks affect XERAVA?

Generic entry risk depends on the current Orange Book listings and any Paragraph IV certifications filed against them. Patent litigation could focus on composition, treatment method, manufacturing process, or formulation claims.

Excipient companies face two separate risks:

1. They may supply a generic challenger whose product is alleged to infringe a listed formulation or process patent.
2. They may develop an improved formulation that is blocked by a broad active-ingredient or method-of-use patent.

Settlement agreements can establish a future generic launch date without invalidating the branded company’s patents. Such agreements can also permit limited noninfringing formulations, making formulation design-around work commercially important.

No biosimilar settlement framework applies because eravacycline is a chemically synthesized small molecule rather than a biologic.

How does XERAVA compare with competing intravenous antibiotics?

XERAVA competes with established intravenous options for complicated intra-abdominal infection, including tigecycline, meropenem, imipenem-cilastatin, piperacillin-tazobactam, and other hospital antibiotics.

Product	Primary formulation format	Excipient opportunity
XERAVA	Lyophilized 50 mg vial	Reconstitution, premix, stability, reduced volume
Tigecycline	Lyophilized vial	Similar sterile-powder opportunities; mature generic competition
Meropenem	Powder vial	High generic pressure; compatibility and premix opportunities
Ertapenem	Powder vial	Once-daily administration and premix opportunities
Piperacillin-tazobactam	Powder vial or premix	Large hospital market; strong ready-to-use competition
Newer branded antibiotics	Varies	Delivery convenience and stability remain differentiators

XERAVA’s commercial formulation advantage would be strongest if a new presentation reduced preparation burden or solved fluid-volume and stability constraints. An excipient change that produces no workflow or clinical benefit would face limited purchasing leverage.

Key Takeaways

• XERAVA is a sterile lyophilized eravacycline product supplied in a 50 mg single-dose vial.
• Mannitol and hydrochloric acid are the principal listed inactive ingredients.
• The largest excipient opportunities are ready-to-use bags, improved reconstitution, longer in-use stability, and reduced-volume infusion.
• Conventional mannitol substitution has limited patent value unless linked to a measurable manufacturing or stability benefit.
• A stable liquid formulation, high-concentration formulation, or dual-chamber presentation could support stronger formulation and device protection.
• XERAVA is subject to small-molecule generic competition, not biosimilar competition.
• QIDP status extends qualifying regulatory exclusivity and patent terms, but the commercial entry date depends on the current Orange Book patent estate and any Paragraph IV settlements.
• Sterile lyophilization, container compatibility, light sensitivity, metal-ion control, and aseptic manufacturing are the main technical barriers.
• The strongest commercial strategy combines excipient optimization with delivery-system and pharmacy-workflow improvements.

FAQs

Can XERAVA be reformulated as an oral product?

An oral eravacycline product would require a separate development program addressing bioavailability, gastrointestinal stability, food effects, dose exposure, and clinical bridging. It would not be a simple excipient substitution for the approved intravenous product.

Is mannitol in XERAVA replaceable?

Mannitol could potentially be replaced or combined with another lyophilization excipient, but the substitute would require comparative stability, cake-structure, reconstitution, sterility, and impurity data.

Could a premixed XERAVA bag avoid the original vial formulation patents?

A premixed bag may avoid some lyophilized-vial claims but could still implicate active-ingredient, concentration, method-of-use, process, or formulation claims. Freedom to operate must be assessed against the complete, current patent estate.

Does XERAVA qualify for biosimilar competition?

No. Eravacycline is a chemically synthesized small molecule. Competition would generally proceed through an ANDA or, for a materially different formulation or administration system, a 505(b)(2) application.

What is the most attractive excipient opportunity for XERAVA?

A formulation enabling a stable, ready-to-administer, reduced-volume infusion has the strongest commercial profile because it can reduce pharmacy labor, improve use in fluid-restricted patients, and create a differentiated product presentation.

References

1. U.S. Food and Drug Administration. (2024). XERAVA (eravacycline) for injection, prescribing information. Tetraphase Pharmaceuticals, Inc.

2. U.S. Food and Drug Administration. (2018, August 27). FDA approves new antibacterial drug for complicated intra-abdominal infections. https://www.fda.gov

3. U.S. Food and Drug Administration. (2024). Qualified Infectious Disease Product designation and exclusivity provisions. https://www.fda.gov

4. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations, Orange Book. https://www.accessdata.fda.gov/scripts/cder/ob/index.cfm